Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

BioAscent Discovery Ltd.. (8/29/18). "Press Release: BioAscent Appoints New Directors of Chemistry and Biosciences to Lead Integrated Drug Discovery Services". Newhouse.

Organisations Organisation BioAscent Discovery Ltd.
  Group BioCity (GB) (Group)
  Organisation 2 University of Dundee, European Screening Centre, Newhouse at BioCity Scotland (European Lead Factory)
  Group University of Dundee
Products Product drug discovery services
  Product 2 chemical services
Persons Person Morrison, Angus (BioCity 201808– Director of Chemistry at BioAscent before European Screening Centre Newhouse)
  Person 2 McElroy, Stuart (BioCity 201808– Director of Biosciences at BioAscent before European Screening Centre Newhouse)
     


BioAscent Discovery Limited (www.bioascent.com) has announced the appointments of Angus Morrison, PhD, as Director of Chemistry and Stuart McElroy, PhD, as Director of Biosciences, to oversee the development and delivery of BioAscent’s integrated drug discovery services.

Drs Morrison and McElroy will head up BioAscent’s teams of expert medicinal chemists and biologists, who have extensive experience working in major pharma and biotech and a track record of taking drugs from concept to clinical candidate

Angus Morrison joins BioAscent from the European Screening Centre, Newhouse where, as Head of Chemistry, he was responsible for over 30 hit-to-lead programmes. Prior to this, Angus held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology. During his time in pre-clinical drug discovery he has worked across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination. Dr Morrison is a co-author on over 30 papers and patents.

Stuart McElroy has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit-to-lead and lead optimisation programmes. Before joining BioAscent, Stuart was Head of Biology at the European Screening Centre, where he led a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Previously Stuart helped establish the Dundee Drug Discovery Unit (DDU), working across a wide array of novel drug targets and assays in partnerships between the DDU and both large pharma and SMEs.

Paul Smith, BioAscent’s CEO, said: “Under Stuart and Angus’s leadership our biosciences and medicinal chemistry teams offer world-class expertise and proven ability to deliver. Together with our state-of-the-art compound management, screening and chemistry facilities, as well as our on-site Compound Cloud library, BioAscent is an ideal partner for both large and small pharmaceutical and biotechnology companies.”

For more information please about BioAscent’s integrated drug discovery services, visit www.bioascent.com.

ENDS======================================


Editors’ Notes

BioAscent Discovery Ltd.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1 million compounds for our customers, in both liquid and solid formats. Through the Compound Cloud service, the company provides rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Since 2013, the BioAscent team has been responsible for:

>100 biochemical and biophysical assays for drug discovery projects

>50 hit validation/characterisation projects

>30 hit-to-lead campaigns

>80,000 screening plates delivered to our global customers/partners


Ref 1804BIO

Product Enquiries

BioAscent Discovery Ltd.
Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH, UK
t:+44 (0) 1698 534 002
e: mailto:info@bioascent.com
w: www.bioascent.com

Media enquiries

Alto Marketing Limited
David Robinson
t: +44 (0)1489 557672
e: davidr@alto-marketing.com
w: www.alto-marketing.com

   
Record changed: 2018-09-05

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for BioCity (GB) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top